Based on accumulating evidence, elucidating the mechanisms underlying the aberrant overexpression of LY6E in cancer cells will provide an insight into the development of rational strategies that target the LY6E-HIF-1 axis for cancer therapy. This evidence concerns the gene HIF1A and cancer.